Log In
BCIQ
Print this Print this
 

IMO-9200 oral

  Manage Alerts
Collapse Summary General Information
Company Idera Pharmaceuticals Inc.
DescriptionToll-like receptor 7 (TLR7), TLR8 and TLR9 antagonist
Molecular Target Toll-like receptor 7 (TLR7) ; Toll-like receptor 8 (TLR8)
Mechanism of ActionToll-like receptor 8 (TLR8) antagonist; Toll-like receptor 7 (TLR7) antagonist; Toll-like receptor 9 (TLR9) antagonist
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today